Disability rights and experiential use of psychedelics in clinical research and practice.
Npj mental health research July 2, 2024 Maryam Golafshani, Daniel Z Buchman, M Ishrat Husain 3 citations
A disability-rights perspective is brought to the debate about whether psychedelic-assisted psychotherapy (PAP) researchers and clinicians should have personal experience with psychedelics. The authors argue that mandating or implying such experience can perpetuate ableism, because many psychiatric conditions and medications, including common antidepressants, may prevent safe psychedelic use. The field must prioritize disability inclusion among researchers and clinicians as PAP research and practice expand.